Detuned Interferon Alpha-2 Variants for Targeted Immune Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Cytokines like IFNA2, used in immuno-oncology and infectious disease treatments, face challenges with modest efficacy and significant toxicities due to immune activation in healthy tissues, necessitating targeted therapeutic agents with reduced receptor affinity to minimize adverse side effects.
Innovation Solution
Development of human interferon alpha-2 (IFNA2) variants with decreased affinity for the IFNAR2 receptor, achieved through high-throughput screening, allowing localized immune activation at specific cell types by linking cytokines to antibodies targeting cell surface markers, thereby reducing toxicity and enhancing therapeutic index.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Power
If wild-type IFNA2 is used for therapeutic treatment, then immune activation potency is achieved, but toxicity and adverse side effects occur due to immune activation in healthy tissues
Solution Approach 1:
The patent applies local quality by creating IFNA2 variants with differentiated binding affinities - 'detuned' variants with weakened affinity for IFNAR2 and 'tuned' variants with enhanced affinity. This allows the same cytokine to have different activity levels in different contexts, enabling targeted immune activation at the tumor site while minimizing activation in healthy tissues, thus resolving the contradiction between potency and toxicity
Solution Approach 2:
The patent changes the binding affinity parameter of IFNA2 through amino acid substitutions. By modifying specific residues in the IFNA2 sequence, the invention creates variants with altered receptor binding characteristics. This parameter change enables the cytokine to maintain therapeutic efficacy while reducing off-target effects, directly addressing the toxicity issue
2Reliability
If IFNA2 affinity for IFNAR2 is decreased to reduce toxicity, then therapeutic index is improved, but immune activation efficacy may be reduced
Solution Approach 1:
The patent creates a dynamic system where IFNA2 variants can be selected and combined based on therapeutic needs. The 'detuned' and 'tuned' variants work in concert - the detuned variant provides safety by reducing background activation, while the tuned variant provides efficacy by concentrating activity at the target site. This dynamic combination allows the system to achieve both improved therapeutic index and maintained efficacy
Solution Approach 2:
The patent uses the antibody component as an intermediary that delivers the IFNA2 variant to the target cell surface. The antibody-IFNA2 fusion protein ensures that the cytokine is positioned close to its receptor, compensating for the reduced affinity of detuned variants. This intermediary mechanism allows the system to achieve both reduced toxicity and maintained efficacy
Data Source
AI summary
Provided herein are human interferon alpha-2 (IFNA2) variants that have decreased or no detectable binding to the human interferon-alpha/beta receptor beta 2 (IFNAR2) as compared to the wild-type human IFNA2 polypeptide. Also provided herein are fusion proteins comprising an antibody or fragment thereof, and a human IFNA2 variant, wherein the IFNA2 variant is covalently linked to the antibody, and wherein the IFNA2 variant has decreased or no detectable binding to the human interferon-alpha/beta receptor beta (IFNAR2) as compared to the wild-type human IFNA2 polypeptide.